03 January 2020
Visiongain has published a new pharma report Top 25 Anaesthesia Drugs Manufacturers 2020: Novartis, Mylan, Teva, Merck and Other Companies.
The Global Anaesthesia Drugs Market is estimated to grow at a CAGR of 3.9% from 2019 to 2024, dominated by the local anaesthesia submarket. The global anaesthesia drugs market is projected to grow at lucrative rate during the forecast period owing to a rising number of surgical procedures globally, developing healthcare infrastructure in emerging economies, and growing number of geriatric population.
This report profiled the selected companies: Abbott Laboratories, AbbVie, Aspen Pharmacare, AstraZeneca, B. Braun Melsungen AG, Baxter International, Boehringer Ingelheim, Eisai, Endo International and other companies.
The lead analyst commented that "Advancements in the anaesthesia drug delivery methods, such as jet injection, inhalation and computer-controlled anaesthesia delivery systems will further encourage the general anaesthesia drugs industry. Over the years, the emergence of new medications, technology, and knowledge has revolutionized perioperative medicine, and as a consequence, interest in how these changes affect anaesthetic care and practice has emerged."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.
01 July 2020
Various research studies are currently underway, which are expected to create a competitive advantage for manufacturers to develop new and innovative and advanced software that is expected to provide a variety of additional opportunities in the perinatal clinical software market.
01 July 2020
Growing investment in target diagnosis of cardiovascular disorders, TB and diabetes drives demand for clinical laboratory testing. Clinical lab tests help in diagnosing mellitus diabetes. According to the International Diabetes Federation article published in 2019, some 463 million adults were diabetic, and it is estimated that it will reach 700 million worldwide by 2045.